Compare Regeneron Pharmaceuticals Inc (REGN) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Symbotic Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Symbotic Inc trades at $42.52 (market cap $5.45B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 13× Symbotic Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals.
| REGN | SYM | |
|---|---|---|
Market Cap | $70.79B | $5.45B |
Sector | Health | Technology |
52-Week High | $812.27 | $87.30 |
52-Week Low | $545.46 | $38.57 |
Enterprise Value | $64.74B | $3.44B |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
SYM trades at $40.83, down 1.02% with bearish technical signals despite recent earnings beats. The company shows revenue growth potential with $2.25B in 2025 revenue and improving margins, though net income remains negative. Analyst consensus is bullish with a $57.50 price target, while technical indicators show oversold conditions with RSI at 29.43. Recent news highlights Symbotic's positioning in warehouse robotics and AI automation.
The stock presents a growth opportunity in the expanding warehouse automation market, supported by strong analyst buy ratings and improving financial trends. Key risks include continued negative profitability, high valuation multiples, and competitive pressures in the robotics sector. Near-term catalysts include Q2 2026 earnings and execution on the company's $1.1B projected net cash flow for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
